MTA1-activated Epi-microRNA-22 Regulates E-cadherin and Prostate Cancer Invasiveness
Overview
Authors
Affiliations
We have previously shown that metastasis-associated protein 1 (MTA1), a chromatin remodeler, plays an important role in prostate cancer invasiveness, likely through regulation of epithelial-to-mesenchymal transition. Here, we identified miR-22 as an epigenetic-microRNA (Epi-miR) directly induced by MTA1 and predicted to target E-cadherin. Loss-of-function and overexpression studies of MTA1 reinforced its regulatory role in miR-22 expression. MiR-22 directly targets the 3'-untranslated region of E-cadherin, and ectopic overexpression of miR-22 diminishes E-cadherin expression. Overexpression of miR-22 in prostate cancer cells promotes cell invasiveness and migration. Meta-analysis of patient tumor samples indicates a positive correlation between MTA1 and miR-22, supporting their inhibitory effect on E-cadherin expression. Our findings implicate the MTA1/Epi-miR-22/E-cadherin axis as a new epigenetic signaling pathway that promotes tumor invasion in prostate cancer.
Logotheti S, Papadaki E, Zolota V, Logothetis C, Vrahatis A, Soundararajan R Cancers (Basel). 2023; 15(17).
PMID: 37686633 PMC: 10486655. DOI: 10.3390/cancers15174357.
The Bone Microenvironment Soil in Prostate Cancer Metastasis: An miRNA Approach.
Prigol A, Rode M, da Luz Efe F, Saleh N, Creczynski-Pasa T Cancers (Basel). 2023; 15(16).
PMID: 37627055 PMC: 10452124. DOI: 10.3390/cancers15164027.
LINC01088/miR-22/CDC6 Axis Regulates Prostate Cancer Progression by Activating the PI3K/AKT Pathway.
Li J, Huang X, Chen H, Gu C, Ni B, Zhou J Mediators Inflamm. 2023; 2023:9207148.
PMID: 37501932 PMC: 10371595. DOI: 10.1155/2023/9207148.
An Immunocompetent Environment Unravels the Proto-Oncogenic Role of miR-22.
Centomo M, Vitiello M, Poliseno L, Pandolfi P Cancers (Basel). 2022; 14(24).
PMID: 36551740 PMC: 9776418. DOI: 10.3390/cancers14246255.
Gnetin C Intercepts MTA1-Associated Neoplastic Progression in Prostate Cancer.
Parupathi P, Campanelli G, Deabel R, Puaar A, Devarakonda L, Kumar A Cancers (Basel). 2022; 14(24).
PMID: 36551523 PMC: 9775406. DOI: 10.3390/cancers14246038.